Febuxostat Tablets 40mg, 80mg, 160mg Tablet

What is Febuxostat Tablets 40mg, 80mg, 160mg Tablet?

Febuxostat Tablets 40mg, 80mg, 160mg Tablet contains febuxostat, a xanthine oxidase inhibitor used to reduce elevated uric acid levels. Available in 40 mg, 80 mg, and 160 mg strengths, these tablets may be used in the management of chronic hyperuricemia associated with gout, according to the approved product information and healthcare professional guidance.

Uses / Indications

Febuxostat tablets may be indicated for the management of chronic hyperuricemia in patients with gout. By reducing uric acid production, febuxostat may help maintain uric acid levels within the target range specified by the treating healthcare professional.

Use should follow the approved product information and the advice of a qualified healthcare professional.

Benefits

• Helps reduce the production of uric acid in the body.
• Supports management of chronic hyperuricemia associated with gout.
• Available in multiple strengths: 40 mg, 80 mg, and 160 mg.
• Suitable for pharmaceutical sourcing requirements in the specified tablet dosage form and pack configurations.
• May support long-term urate-lowering therapy when prescribed and monitored appropriately.

Side Effects

Common Side Effects

Possible side effects may include:

• Nausea
• Diarrhea
• Headache
• Skin rash
• Joint-related discomfort, particularly during the initial period of urate-lowering treatment
• Changes in liver function tests

Less Common or Serious Side Effects

Serious reactions can occur in some individuals and may include severe skin reactions, allergic reactions, liver-related problems, or cardiovascular events.

Seek prompt medical attention for symptoms such as facial or throat swelling, difficulty breathing, extensive blistering or peeling of the skin, severe rash, yellowing of the skin or eyes, dark urine, or other severe or unusual symptoms.

How Does It Work?

Febuxostat works primarily by inhibiting xanthine oxidase, an enzyme involved in the conversion of purines into uric acid.

By reducing xanthine oxidase activity, febuxostat decreases the production of uric acid and helps lower elevated serum urate levels. This action supports long-term urate management in appropriate patients with gout and hyperuricemia.

Dosage Guidelines

The appropriate strength and dosing schedule depend on the patient’s uric acid level, clinical condition, treatment response, kidney and liver function, age, and other medicines being used.

Febuxostat should be taken exactly as prescribed. Tablets should generally be swallowed with water and should not be crushed, split, or chewed unless permitted by the approved product information.

Patients should not independently change between the 40 mg, 80 mg, or 160 mg strengths.

The exact dose and treatment duration should follow the approved product information and the recommendation of a qualified healthcare professional.

When Not to Use

Febuxostat should not be used in individuals with a known hypersensitivity to febuxostat or any component of the product.

Certain combinations, including some medicines that are significantly affected by xanthine oxidase inhibition, may be inappropriate. The complete approved product information should be reviewed before use.

Patients with significant cardiovascular disease, liver disease, kidney impairment, or other important medical conditions should inform their healthcare professional before treatment.

Drug / Product Interactions

Relevant interaction considerations may include:

• Azathioprine or mercaptopurine: Concomitant use can cause clinically significant increases in exposure to these medicines and may be contraindicated.
• Theophylline: Its metabolism may be affected and appropriate clinical consideration may be required.
• Other urate-lowering medicines: Combined treatment should only be used when specifically prescribed.
• Other prescription medicines, over-the-counter products, or supplements should be reviewed by a healthcare professional before starting treatment.

Safety Advice

• Use febuxostat only according to the approved product information and professional medical advice.
• Patients with cardiovascular disease should discuss their medical history with their healthcare professional before treatment.
• Liver function may require monitoring in appropriate patients.
• Inform the healthcare professional about existing kidney or liver problems.
• During pregnancy or breastfeeding, use should be based on professional medical assessment.
• Children should receive febuxostat only when specifically indicated under appropriate medical supervision.
• Older adults may require careful consideration of existing medical conditions and concurrent medicines.
• Avoid unnecessary alcohol consumption if it may worsen gout or interfere with the overall treatment plan.
• If dizziness or other symptoms affecting alertness occur, use caution with driving or operating machinery.
• Do not discontinue long-term urate-lowering treatment without discussing it with a healthcare professional.
• If an overdose is suspected, seek immediate medical attention or contact an appropriate poison-control or emergency medical service.

General Instructions

• Take the tablet according to the prescribed schedule.
• Take it with water unless otherwise directed.
• Take doses consistently at the recommended time.
• Do not take a double dose to compensate for a missed dose.
• Continue treatment according to the prescribed plan even when gout symptoms are not present, unless advised otherwise by a healthcare professional.
• Regular monitoring may be recommended to assess serum uric acid and other relevant clinical parameters.

Special Dietary / Lifestyle Tips

• Maintain adequate hydration unless fluid restriction has been advised.
• Follow a balanced diet appropriate for gout and uric acid management.
• Limiting excessive intake of alcohol may be beneficial for people with gout.
• Follow healthcare-professional guidance regarding foods and beverages that may contribute to elevated uric acid levels.
• Maintaining a healthy body weight and regular physical activity may support overall metabolic health.

Comparison with Other Treatments

Febuxostat and other urate-lowering medicines may differ in their mechanism of action, dosing requirements, interactions, and suitability for individual patients. Febuxostat specifically lowers uric acid production through xanthine oxidase inhibition.

Treatment selection depends on factors such as serum uric acid levels, kidney and liver function, cardiovascular history, concurrent medicines, tolerability, and the patient’s clinical requirements. A healthcare professional should determine the appropriate urate-lowering approach.

Precautions & Warnings

• Review any history of cardiovascular disease before treatment.
• Monitor for signs of hypersensitivity or severe skin reactions.
• Liver function should be evaluated when clinically appropriate.
• Inform the healthcare professional about kidney or liver impairment.
• Review all current medicines for potential interactions.
• Gout flares may occur after initiation of urate-lowering therapy as urate deposits begin to change; this does not necessarily mean that treatment should be stopped.
• Do not use a different strength or change the treatment schedule without professional guidance.
• Product details should be confirmed against the approved product specification.

Can I Use It With Other Medicines?

Febuxostat can interact with certain medicines, and the complete medication history should be reviewed before treatment.

Generally Compatible With

Many medicines may be used alongside febuxostat when clinically appropriate, but compatibility depends on the patient’s medical history, dose, and complete medication profile.

Use With Caution / Avoid

Particular attention is required with medicines such as azathioprine, mercaptopurine, and theophylline. Some combinations may be contraindicated or require specific medical assessment.

Always inform the healthcare professional about prescription medicines, over-the-counter products, vitamins, and supplements being used.

Storage

Store according to the storage conditions stated on the approved product label and package insert.

• Keep the tablets in their original packaging until use.
• Protect the product from unsuitable environmental conditions as specified on the approved label.
• Keep out of reach of children.
• Do not use tablets after the expiry date stated on the packaging.

Frequently Asked Questions

1. What is Febuxostat Tablets 40mg, 80mg, 160mg Tablet used for?

Febuxostat tablets are used for the management of chronic hyperuricemia associated with gout by reducing uric acid production.

2. What strengths of Febuxostat tablets are available?

The supplied product information includes 40 mg, 80 mg, and 160 mg strengths.

3. How does febuxostat reduce uric acid?

Febuxostat inhibits xanthine oxidase, an enzyme involved in uric acid production, thereby reducing the formation of uric acid.

4. Can febuxostat be used during a gout flare?

The management of an acute gout flare and long-term urate-lowering treatment are different clinical considerations. The appropriate approach should be determined by a qualified healthcare professional.

5. Can Febuxostat tablets be taken with other medicines?

Some medicines can interact significantly with febuxostat. In particular, medicines such as azathioprine and mercaptopurine require careful consideration. The complete medication list should be reviewed by a healthcare professional.

6. Is monitoring required during febuxostat treatment?

Healthcare professionals may monitor serum uric acid and, when appropriate, liver function and other clinical parameters during treatment.

7. Can the 40 mg, 80 mg, and 160 mg strengths be substituted freely?

No. Different strengths should not be substituted or changed without appropriate professional direction because the required dose depends on the individual treatment plan.

8. How should Febuxostat tablets be stored?

They should be stored according to the conditions stated on the approved product label and package insert and kept in their original packaging.